FDA COULD FIND COMPROMISE ON OFF-LABEL PROMOTION, KESSLER INDICATES; INDUSTRY EXEC SAYS LEGISLATION NEEDS TO INCREASE "VALUE" OF APPROVED LABELING
Executive Summary
FDA may be willing to allow off-label promotion of indications where there is no financial incentive to support new studies, Commissioner Kessler indicated during his May 1 testimony to the House Commerce/Health Subcommittee.